Oxybutynin vaginal - FemmePharma

Drug Profile

Oxybutynin vaginal - FemmePharma

Alternative Names: FP 1097

Latest Information Update: 10 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FemmePharma
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Urinary incontinence

Most Recent Events

  • 10 Jun 2015 FemmePharma is planning a phase III trial for Urinary incontinence in the US
  • 11 Jan 2011 Efficacy and adverse events data from a phase II trial in urinary incontinence released by FemmePharma
  • 11 Jan 2011 FemmePharma completes a phase II trial in urinary incontinence in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top